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Brittle cornea syndrome: A systemic review of disease-causing mutations in 
ZNF469 and two novel variants identified in a patient followed for 26 years
Pavlina Skalickaa,b, Louise F. Porterc,d, Kristyna Brejchovaa, Frantisek Malinkaa,e, Lubica Dudakovaa, Petra Liskovaa,b
Aims. Brittle cornea syndrome (BCS) is a rare autosomal recessive disorder. The aim of this study was to review ZNF469 
mutations associated with BCS type 1 to date and to describe an additional case of Czech/Polish background.
Methods. Whole genome sequencing was undertaken to identify the molecular genetic cause of disease in the pro-
band. Sequence variants in ZNF469 previously reported as BCS type 1-causing were searched in the literature, manually 
curated and aligned to the reference sequence NM_001127464.2. 
Results. The proband has been reviewed since childhood with progressive myopia and hearing loss. Aged 13 years 
had been diagnosed with Stickler syndrome. Aged 16.5 years, he developed acute hydrops in the left eye managed 
by corneal transplantation. At the age of 26, he experienced right corneal rupture after blunt trauma, also managed 
by grafting. He had a number of secondary complications and despite regular follow-up and timely management, the 
right eye became totally blind and the left eye had light perception at the last follow-up visit, aged 42. He was found to 
be a compound heterozygote for two novel mutations c.1705C>T; p.(Gln569*) and c.1402_1411del; p.(Pro468Alafs*31) 
in ZNF469. In total 22 disease-causing variants in ZNF469 have been identified, mainly in consanguineous families or 
endogamous populations. Only four probands, including the case described in the current study, harboured compound 
heterozygous mutations. 
Conclusion. BCS occurs very rarely in outbred populations which may cause diagnostic errors due to poor awareness 
of the disease. Investigation into the underlying molecular genetic cause in patients with connective tissue disorders 
may lead to a re-evaluation of their clinical diagnosis. 
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INTRODUCTION
Brittle cornea syndrome (BCS) is a rare generalized 
connective tissue disorder inherited as an autosomal re-
cessive trait. Clinical ocular features include fragile thin 
ectatic corneas and blue sclerae. Variable commonly 
associated extraocular manifestations comprise skeletal 
and/or connective tissue abnormalities, such as joint hy-
permobility with occasional dislocations, kyphoscoliosis, 
hyperlaxity of the skin, dental abnormalities and hearing 
loss which develops in around one third of cases1,2.
Mutations within two genes ZNF469 (ref.2,3) and 
PRDM5 (ref.4,5) are known to be associated with BCS 
type 1 (BCS1; MIM #229200) and type 2 (BCS2; MIM 
#614170), respectively. The disease mechanism remains 
unclear. Both encoded proteins ZNF469 and PRDM5 
are transcription factors regulating extracellular matrix 
components, particularly fibrillar collagens suggesting 
involvement in the same pathway3,5,6. 
In this review we summarize and evaluate for patho-
genicity using recent bioinformatics tools all variants in 
ZNF469 previously reported as BCS1-causing includ-
ing two novel ZNF469 mutations identified in a case of 
Czech/Polish descent under ophthalmic review for 26 
years. 
MATERIALS AND METHODS
The study was approved by the Ethics committee 
of General University in Prague and adhered to the 
Declaration of Helsinki. Informed consents were signed 
prior to the start of all investigations.
DNA from the proband and participating family mem-
bers was extracted from a venous blood sample using the 
Gentra Puregene blood kit (Qiagen, Hilden, Germany) 
and analysed by genome sequencing using a TruSeq Nano 
DNA library preparation kit and a HiSeq X Ten sequencer 
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Fig. 1. Ocular findings in a patient with brittle cornea syndrome. (A) Narrow slit-beam view of the right cornea with ectasia (age 
16.5 years), (B) right eye after tectonic penetrating keratoplasty, note blue sclerae superior from the corneal limbus (age 26.5), (C) 
opaque right graft with lipoid keratopathy and progression of scleral thinning, (D) in detail (age 42). (E) Acute hydrops in the left 
eye (age 16.5); (F) left graft failure (age 17.5), (G) left eye with a vascularized graft (age 42), (H) detail of blue sclerae (age 42).
Fig. 2. Physical appearance of the patient with brittle cornea syndrome. (A) asthenic habitus (age 26); (B) hands with clinodactyly 
(age 26); (C) feet with hallux valgus (age 26).
(Illumina). FASTQ reads were aligned to the GRCh38/
hg38 human reference sequence using the Burrows-
Wheeler Alignment tool7. Variant calling was performed 
with HaplotypeCaller8. Sequence changes with a minor 
allele frequency <0.005 in ZNF469 and PRDM5 were pri-
oritized for further evaluation. Conventional Sanger se-
quencing was applied to show segregation of the detected 
mutation within the family9. 
Sequence variants previously reported as causing 
BCS1 were searched in the literature, manually curated 
and aligned to the reference sequence NM_001127464.2. 
Missense variants were subjected to in silico analysis us-
ing 6 different tools. The population frequency of the 
variants was retrieved from the Genome Aggregation 
Database (gnomAD), providing sequencing data from 
more than 138,000 unrelated individuals of various ethnic 
backgrounds10, and 4,528 Czech control chromosomes 
available through the projects of the National Center for 
Medical Genomics (https://ncmg.cz/en).
RESULTS 
CASE REPORT
The proband of Czech/Polish descent was under 
ophthalmic review from his 3rd birthday because of pro-
gressive myopia. According to his clinical notes, he was 
diagnosed with bilateral corneal ectasia before the age of 
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Table 1. Ocular surgeries performed in the proband reviewed for 26 years. 
Eye
Age
(years)
Procedure Reason 
Preoperative 
BCVA 
Postoperative 
BCVA (3 months 
after surgery) 
Comment
RE
26.0 Tectonic PK Large corneal perforation 
after blunt trauma
LP 0.16 Graft size 8.5 mm, aphakia 
(lens lost during trauma)
26.0 AMT Wound leakage 0.16 0.16 
26.5 PPV + SO Retinal detachment 0.10 0.25
28.5 CCK Secondary glaucoma LP LP
LE
16.5 PK Corneal hydrops LP 0.16 Graft size 9.0 mm
17.5 rePK Graft failure 0.01 0.01
17.5 TE Secondary glaucoma 0.01 NA Performed 11 days after rePK
20.0 rePK Graft failure LP 0.16 Graft size 6.2 mm
AMT - amniotic membrane transplantation; BCVA - best corrected visual acuity (measured on Snellen charts and extrapolated to decimal values); 
CCK – cyclocryocoagulation; LE - left eye; LP – light projection; PK - penetrating keratoplasty; PPV - pars plana vitrectomy; RE - right eye; rePK 
– repeated penetrating keratoplasty; SO - silicone oil tamponade; TE – trabeculectomy
Table 2. Summary of ZNF469 mutations and individual families with brittle cornea syndrome reported to date. 
DNA level Protein level No of 
affected 
subjects/with 
hearing loss
No. of 
families
Origin Zygosity Consangu- 
inity
Ref.
c.1402_1411del p.(Pro468Alafs*31) 1/1 1 Caucasian Czech/
Polish
Compound 
HET
N Current 
studyc.1705C>T p.(Gln569*)
c.1963dup p.(His655Profs*83) 1/0 1 Not provided Compound 
HET
N 17
c. 6360dup p.(Gln2121Alafs*42)
c.2029G>T p.(Gly677*) 2/0 1 Saudi Arabian HOM Y 1,13
c.2150del p.(Phe717Serfs*15) 3/0 2 Saudi Arabian HOM Y/1, N/1# 1,13#,18
c.3220G>T p.(Glu1074*) 1/1 1 Yemenish HOM Y 1,13
c.3392del p.(Gly1131Alafs*105) 1/1 1 Indian HOM Y 13
c.4174G>T p.(Glu1392*) 2/0 1 Syrian HOM Y 19
c.5269C>T p.(Gln1757*) 3/3 2 Syrian HOM Y 1,13
c.5704del p.(Gln1902Argfs*6) 1/1 1 Caucasian British Compound 
HET
N 13
c.5704dup p.(Gln1902Profs*133)
c.5943del p.(Gly1983Alafs*16) 6/NA 4 Tunisian Jewish HOM Y/3, N/1# 3,20
c.6360del p.(Gln2121Serfs*51) 1/0 1 Pakistani HOM Y 1,13
c.6644delA p.(Asp2215Alafs*8). 1/0 1 Caucasian Compound 
HET
N 12
deletion of 1q24.1
including ZNF469
p.?
c.6563del p.(Gln2188Argfs*21) 2/0 1 Syrian HOM Y 1,13
c.8817_8830dup p.(Glu2944Glyfs*50) 8/4 2 Saudi Arabian HOM Y 1,13,21
c.9399del p.(His3134Thrfs*20) 1/0 1 Saudi Arabian HOM Y 1,13
c.9531del p.(Gln3178Argfs*23) 6/NA 1 Palestinian HOM Y 3
c.10016G>A p.(Cys3339Tyr) 2/2 1 Norwegian HOM Y 2
c.10022G>C p.(Arg3341Pro) 1/0 1 Syrian HOM Y 1,13
HOM = homozygous, HET = heterozygous, Y= yes, N = no, NA = not available
#common founder with other families carrying the same mutation 
All mutations were curated based on original publications and are listed according to the reference sequence NM_001127464.2. Recommendations 
of Human Genome Variation Society were used for description. Information on origin was mined from published reports.
Table 3. In silico analysis of two missense variants in ZNF469. 
DNA level Protein level PolyPhen2 (ref.22)
PROVEAN 
(ref.23)
SIFT (ref.23) MutPred2 (ref.24)
Mutation Taster 
(ref.25)
SNP&GO 
(ref.26)
c.10016G>A p.(Cys3339Tyr) Probably damaging Disease Damaging Disease causing Disease causing Disease
c.10022G>C p.(Arg3341Pro) Probably damaging Neutral Damaging Disease causing Polymorphism Disease
Both mutations were detected in a compound heterozygous state with a truncating mutation in patients with BCS1 (NM_001127464.2).
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13 years. Best corrected visual acuity (BCVA) at the age of 
16 was 0.1 (Snellen decimal conversion) with -23 dioptre 
sphere (DS) in the right eye, and 0.06 with -23 DS x -4.0 
dioptre cylinder in the left eye. At the age of 16.5 years 
he was referred to the Department of Ophthalmology, 
General University Hospital in Prague, with acute corneal 
hydrops in the left eye (Fig. 1E). Blue sclerae were also 
noticed bilaterally (Fig. 1B, H). Right cornea was ectatic 
(Fig. 1A). No other abnormalities of iris, pupil, lens or 
retina were noted. Penetrating keratoplasty was performed 
two months later in view of persistence of the corneal 
edema and light perception visual acuity in the affected 
eye. Unfortunately, the patient suffered from immunologi-
cal rejection and graft failure (Fig. 1F). Two repeated kera-
toplasties were therefore performed at the age of 17.5 and 
20 years complicated by increased intraocular pressure 
(IOP) necessitating trabeculectomy. Eighteen months 
after the third keratoplasty, BCVA was 0.16 in the left 
eye. Thereafter the graft gradually failed (Fig. 1G) and 23 
years following his examination (now aged 42) BCVA in 
the left eye was light perception. IOP remained controlled. 
At the age of 26, the patient experienced right corneal 
rupture with lens dislocation after blunt trauma. Tectonic 
penetrating keratoplasty was performed. Five months af-
ter the surgery, the right retina detached and the patient 
underwent pars plana vitrectomy and silicone oil tampon-
ade. Unfortunately, uncontrollable secondary glaucoma 
caused progressive BCVA decline. The corneal graft in 
the right also failed and became opaque (Fig. 1C). Since 
the age of 32, the right eye was totally blind. Progression 
of scleral ectasia was documented (Fig. 1B,C,D). Table 
Fig. 3. Pedigree and results of molecular genetic testing. (A) Pedigree of the investigated family, sequence 
chromatograms of the heterozygous mutations identified in ZNF469 (B) c.1402_1411del and (C) c.1705C>T. 
Wild type is referred as “wt”.
1 lists all surgeries the patient underwent since the age 
of 16.5 years. 
In addition, the proband had been followed up since 
childhood (11 years of age) for sensorineural hearing 
loss, managed with a hearing aid. Repeated audiometry 
confirmed the presence of moderate symmetrical non-
progressive impairment in both ears with a loss in the 
range of 45-65 dB. Mild worsening was observed with age 
and deemed to be age-associated. 
Transthoracic echocardiography was performed at 
the age of 17 and 26 years. Mitral and tricuspid valve 
insufficiencies were noted but not deemed functionally 
important. Incomplete right bundle branch block was 
also detected on electrocardiography and considered 
benign, not requiring treatment. Aged 26 years the pa-
tient’s height was 190 cm and his weight was 60 kg, with 
concomitant mild kyphoscoliosis, clinodactyly and hallux 
valgus (Fig. 2). No joint subluxations, fractures, abnormal 
contractures or severe bone deformities were found. No 
skin striae, excessive scarring, bruising or abnormal laxity 
were observed. At the age of 31, the proband underwent 
surgery for right scrotal hernia. Of note, he also suffered 
from excessive dental caries since childhood. Details of 
dental examinations were however unavailable.
Importantly, since the age of 13 he had been consid-
ered to be a de novo case of Stickler syndrome. This di-
agnosis remained unchallenged until the age of 40, when 
a clinical diagnosis of BCS based on careful review of his 
past clinical notes was suspected. 
Molecular genetic diagnosis uncovered com-
pound heterozygosity for c.1705C>T; p.(Gln569*) and 
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c.1402_1411del; p.(Pro468Alafs*31) in ZNF469 (Fig.3), 
absent from gnomAD as well as from white Czech con-
trol chromosomes, confirming BCS1. As truncating muta-
tions have been previously associated with BCS1 (Table 
2), these variants were considered pathogenic. Consistent 
with autosomal recessive disease, both parents were het-
erozygous carriers of each detected variants. Two unaf-
fected sisters were also heterozygous carriers (Fig. 3).
Summary of ZNF469 mutations causing BCS1
Including this study, there are 22 different sequence 
variants reported as pathogenic in 24 families with more 
than 40 family members affected by BCS1 (Table 2). 
Only four probands were compound heterozygotes, the 
rest were homozygotes.
None of the mutations had an entry in gnomAD. 
Sixteen reported variants are predicted to result in the 
interruption of translation, consequently leading either 
to a truncation of the encoded protein, or degradation 
of aberrant transcripts by nonsense-mediated mRNA de-
cay11. One mutation was a large deletion encompassing 
the whole ZNF469 gene. Two variants were missense mu-
tations1,12,13. Pathogenicity predictions using six software 
tools supported the disease-causing role of the two mis-
sense mutations (Table 3). 
One additional variant reported as disease-causing 
c.7424C>A; p.(Ala2475Glu) (ref.13) was discarded be-
cause of its high prevalence in the general population 
(minor allele frequency 0.07422, with 567 homozygotes 
reported as per gnomAD), not matching the rarity of 
BCS1.
DISCUSSION
BCS1 is an ultra-rare disease. In addition to a compre-
hensive curation and summary of all 22 disease-causing 
mutations in ZNF469 associated with BCS1 reported to 
date, we present a case harbouring two novel pathogenic 
variants detected by genome sequencing. 
Analysis using current bioinformatic tools, especially 
interrogation of publicly available minor allele frequen-
cies, allowed us to dismiss one ZNF469 variant previously 
associated with BCS1 highlighting the general fact that 
there is a need of re-evaluation of mutational findings 
published before the era of large datasets. BCS1 has been 
caused by homozygous mutations in the great majority 
of families, which is consistent with consanguinity and/
or marriages within endogamous populations. The func-
tion of ZNF469 has not been fully resolved, however the 
importance of the protein on corneal structure and devel-
opment has been recently confirmed, showing association 
with keratoconus and central corneal thickness9,14.
Although the phenotype in our proband was typical it 
took more than two decades to make the correct diagno-
sis. His clinical course confirms the fact that management 
of corneal rupture in BCS is difficult and outcomes are 
usually unsatisfactory despite state-of-the-art treatment15,16. 
It is therefore of utmost importance to recognize BCS 
early, in order to apply preventive measures. As a part of 
our long-term follow-up we have also documented senso-
rineural hearing impairment with no progression other 
than age-related mild decline. 
CONCLUSION
BCS1 occurs very rarely in outbred populations which 
may cause diagnostic errors due to poor awareness of 
the disease. Molecular genetic analysis evolved to be an 
essential part of the diagnostic process in many rare dis-
eases including BCS, and in some cases, it may even lead 
after many years to a correction of the clinical diagnosis. 
Search strategy and selection criteria
Our research strategy was aimed at identifying studies 
reporting on ZNF469 mutations associated with BCS1. 
Scientific articles from 1999 to December 2018 were 
searched using the PubMed and Scopus databases. The 
search terms used included “brittle cornea syndrome”, 
“ZNF469“, “mutation“, “variant“. All relevant articles 
were reviewed. 
Acknowledgement: This work was supported by GAUK 
250361/2017. Institutional support was provided by 
UNCE 204011, SVV 260367/2017 and PROGRES Q26/
LF1 programs of the Charles University. LFP is a clinical 
lecturer funded by NIHR. FM was supported by OP VVV 
MEYS funded project CZ.02.1.01/0.0/0.0/16_019/000
0765 "Research Center for Informatics". We thank The 
National Center for Medical Genomics (LM2015091) 
providing ethnically matched population frequency data 
(project CZ.02.1.01/0.0/0.0/16_013/0001634). 
Author contributions: PS: manuscript writing, data col-
lection; LFP: manuscript writing, data collection and 
analysis, KB: manuscript writing, figure preparation and 
literature search, FM: manuscript writing, statistical analy-
sis, LD: manuscript writing, figure preparation and PL 
manuscript writing, study design.
Conflict of interest statement: The authors state that there 
are no conflicts of interest regarding the publication of 
this article. 
REFERENCES
 1. Al-Hussain H, Zeisberger SM, Huber PR, Giunta C, Steinmann B. 
Brittle cornea syndrome and its delineation from the kyphoscoliotic 
type of Ehlers-Danlos syndrome (EDS VI): report on 23 patients and 
review of the literature. Am J Med Genet A 2004;124A:28-34.
 2. Christensen AE, Knappskog PM, Midtbo M, Gjesdal CG, Mengel-From 
J, Morling N, Rødahl E, Boman H. Brittle cornea syndrome associ-
ated with a missense mutation in the zinc-finger 469 gene. Invest 
Ophthalmol Vis Sci 2010;51:47-52.
 3. Abu A, Frydman M, Marek D, Pras E, Nir U, Reznik-Wolf H, Pras E. 
Deleterious mutations in the Zinc-Finger 469 gene cause brittle 
cornea syndrome. Am J Hum Genet 2008;82:1217-22.
 4. Burkitt Wright EMM, Spencer HL, Daly SB, Manson FDC, Zeef LAH, 
Urquhart J, Zoppi N, Bonshek R, Tosounidis I, Mohan M, Madden 
C, Dodds A, Chandler KE, Banka S, Au L, Clayton-Smith J, Khan N, 
Biesecker LG, Wilson M, Rohrbach M, Colombi M, Giunta C, Black 
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019; 163:XX.
6
GCM. Mutations in PRDM5 in brittle cornea syndrome identify 
a pathway regulating extracellular matrix development and main-
tenance. Am J Hum Genet 2011;88:767-77.
 5. Porter LF, Gallego-Pinazo R, Keeling CL, Kamieniorz M, Zoppi N, 
Colombi M, Giunta C, Bonshek R, Manson FD, Black GCM. Bruch's 
membrane abnormalities in PRDM5-related brittle cornea syn-
drome. Orphanet J Rare Dis 2015;10:145.
 6. Galli GG, Honnens de Lichtenberg K, Carrara M, Hans W, Wuelling 
M,  Mentz B,  Multhaupt HA,  Fog CK,  Jensen KT,  Rappsilber 
J, Vortkamp A, Coulton L, Fuchs H, Gailus-Durner V, Hrabě de Angelis 
M, Calogero RA, Couchman JR, Lund. Prdm5 regulates collagen gene 
transcription by association with RNA polymerase II in developing 
bone. PLoS Genet 2012;8:e1002711.
 7. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics 2010;26:589-95.
 8. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, 
Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, 
Garimella KV, Altshuler D, Gabriel S, DePristo MA. From FastQ data to 
high confidence variant calls: the Genome Analysis Toolkit best prac-
tices pipeline. Curr Protoc Bioinformatics 2013;43:11.10.1-11.10.33. 
doi: 10.1002/0471250953.bi1110s43
 9. Lechner J, Porter LF, Rice A, Vitart V, Armstrong DJ, Schorderet DF, 
Munier FL, Wright AF, Inglehearn CF, Black GC, Simpson DA, Manson 
F, Willoughby CE. Enrichment of pathogenic alleles in the brittle cor-
nea gene, ZNF469, in keratoconus. Hum Mol Genet 2014;23:5527-
5535.
10. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, 
O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, 
Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, 
Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do, 
Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, 
Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, 
Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, 
Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd 
B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, 
Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman 
CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, 
McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, 
Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, 
Daly MJ, MacArthur DG; Exome Aggregation Consortium. Analysis 
of protein-coding genetic variation in 60,706 humans. Nature 
2016;536:285-91.
11. Hug N, Longman D, Caceres JF. Mechanism and regulation of the 
nonsense-mediated decay pathway. Nucleic Acids Res 2016;44:1483-
95.
12. Ramappa M, Wilson ME, Rogers RC, Trivedi RH. Brittle cornea syn-
drome: a case report and comparison with Ehlers Danlos syndrome. 
J AAPOS 2014;18:509-11.
13. Rohrbach M, Spencer HL, Porter LF, Burkitt-Wright EM, Bürer C, 
Janecke A, Bakshi M, Sillence D, Al-Hussain H, Baumgartner M, 
Steinmann B, Black GC, Manson FD, Giunta C. ZNF469 frequently 
mutated in the brittle cornea syndrome (BCS) is a single exon gene 
possibly regulating the expression of several extracellular matrix 
components. Mol Genet Metab 2013;109:289-95.
14. Davidson AE, Borasio E, Liskova P, Khan AO, Hassan H, Cheetham 
ME, Plagnol V, Alkuraya FS, Tuft SJ, Hardcastle AJ. Brittle cornea syn-
drome ZNF469 mutation carrier phenotype and segregation analysis 
of rare ZNF469 variants in familial keratoconus. Invest Ophthalmol 
Vis Sci 2015;56:578-86.
15. Burkitt Wright EM, Porter LF, Spencer HL, Clayton-Smith J, Au L, 
Munier FL, Smithson S, Suri M, Rohrbach M, Manson FD, Black GC. 
Brittle cornea syndrome: recognition, molecular diagnosis and man-
agement. Orphanet J Rare Dis 2013;8:68.
16. Izquierdo L, Jr., Mannis MJ, Marsh PB, Yang SP, McCarthy JM. Bilateral 
spontaneous corneal rupture in brittle cornea syndrome: a case re-
port. Cornea 1999;18:621-4.
17. Menzel-Severing J, Meiller R, Kraus C, Trollmann R, Atalay D. Brittle 
cornea syndrome type 1 caused by compound heterozygosity of 
two mutations in the ZNF469 gene. Ophthalmologe 2018 Oct 18. 
doi: 10.1007/s00347-018-0796-8 [Epub ahead of print] [Article in 
German]
18. Khan AO, Aldahmesh MA, Alkuraya FS. Brittle cornea without clin-
ically-evident extraocular findings in an adult harboring a novel 
homozygous ZNF469 mutation. Ophthalmic Genet 2012;33:257-9.
19. Khan AO, Aldahmesh MA, Mohamed JN, Alkuraya FS. Blue sclera 
with and without corneal fragility (brittle cornea syndrome) in a con-
sanguineous family harboring ZNF469 mutation (p.E1392X). Arch 
Ophthalmol 2010;128:1376-9.
20. Abu A, Frydman M, Marek D, Pras E, Stolovitch C, Aviram-Goldring A, 
Rienstein S, Reznik-Wolf H, Pras E. Mapping of a gene causing brittle 
cornea syndrome in Tunisian jews to 16q24. Invest Ophthalmol Vis 
Sci 2006;47:5283-7.
21. Al-Owain M, Al-Dosari MS, Sunker A, Shuaib T, Alkuraya FS. 
Identification of a novel ZNF469 mutation in a large family with 
Ehlers-Danlos phenotype. Gene 2012;511:447-50.
22. PolyPhen-2. Prediction of functional effects of human nsSNPs. http://
genetics.bwh.harvard.edu/pph2/ (accessed12/2018).
23. PROVEAN (Protein Variation Effect Analyzer): a software tool which 
predicting whether an amino acid substitution or indel has an im-
pact on the biological function of a protein. It also shows SIFT pre-
dictions when precomputed scores are available. http://provean.
jcvi.org/protein_batch_submit.php?species=human (accessed 
12/2018).
24. MutPred2. Predict the pathogenicity of amino acid substitutions and 
their molecular mechanisms. http://mutpred.mutdb.org/#qform
25. Mutation Taster: The free web-based application to evaluate DNA 
sequence variants for their disease-causing potential. http://www.
mutationtaster.org/ (accessed 12/2018)
26. SNP&GO: Predicting disease associated variations using GO terms. 
http://snps.biofold.org/snps-and-go/snps-and-go.html (accessed 
12/2018)
